Jiang Y et al. have recently reported that chronic hepatitis C patients who received long-term lithium carbonate therapy primarily for concomitant psychiatric disorders exhibit significantly less liver injury [14], providing an interesting opportunity for the combination of LiCl and hyperoside or other Nrf2 inducers to reduce the adverse effects of LiCl. Here, NFE2L2 is linked to chronic hepatitis C virus infection.